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Abstract
Background: Previous studies based on local case series estimated the annual incidence of endocarditis in the U.S. at about
4 per 100,000 population. Small-scale studies elsewhere have reported similar incidence rates. However, no nationally-
representative population-based studies have verified these estimates.
Methods and Findings: Using the 1998–2009 Nationwide Inpatient Sample, which provides diagnoses from about 8 million
U.S. hospitalizations annually, we examined endocarditis hospitalizations, bacteriology, co-morbidities, outcomes and costs.
Hospital admissions for endocarditis rose from 25,511 in 1998 to 38, 976 in 2009 (12.7 per 100,000 population in 2009). The
age-adjusted endocarditis admission rate increased 2.4% annually. The proportion of patients with intra-cardiac devices rose
from 13.3% to 18.9%, while the share with drug use and/or HIV fell. Mortality remained stable at about 14.5%, as did cardiac
valve replacement (9.6%). Other serious complications increased; 13.3% of patients in 2009 suffered a stroke or CNS
infection, and 5.5% suffered myocardial infarction. Amongst cases with identified pathogens, Staphylococcus aureus was
the most common, increasing from 37.6% in 1998 to 49.3% in 2009, 53.3% of which were MRSA. Streptococci were
mentioned in 24.7% of cases, gram-negatives in 5.6% and Candida species in 1.0%. We detected no inflection in
hospitalization rates after changes in prophylaxis recommendations in 2007. Mean age rose from 58.6 to 60.8 years; elderly
patients suffered higher rates of myocardial infarction and death, but slightly lower rates of Staphylococcus aureus
infections and neurologic complications. Our study relied on clinically diagnosed cases of endocarditis that may not meet
strict criteria. Moreover, since some patients are discharged and readmitted during a single episode of endocarditis, our
hospitalization figures probably slightly overstate the true incidence of this illness.
Conclusions: Endocarditis is more common in the U.S. than previously believed, and is steadily increasing. Preventive efforts
should focus on device-associated and health-care-associated infections.
Citation: Bor DH, Woolhandler S, Nardin R, Brusch J, Himmelstein DU (2013) Infective Endocarditis in the U.S., 1998–2009: A Nationwide Study. PLoS ONE 8(3):
e60033. doi:10.1371/journal.pone.0060033
Editor: Heiman Frank Louis Wertheim, Oxford University, Vietnam
Received November 20, 2012; Accepted February 22, 2013; Published March 20, 2013
Copyright:  2013 Bor et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: dhimmels@hunter.cuny.edu
Introduction
William Osler’s 1885 study of malignant endocarditis patients at
Montreal General Hospital set a standard for clinical-pathophys-
iological correlation [1]. Subsequent studies using modern
microbiological techniques and echocardiography have docu-
mented dramatic shifts in the profile of this disease [2–7] from
predominantly sub-acute streptococcal infections of younger
women with rheumatic heart disease to acute staphylococcal
illnesses of older men with degenerative heart diseases or
intravascular devices. These data have informed recommendations
regarding prophylaxis and therapy.
Endocarditis incidence estimates have come from studies at
referral hospitals [5] or from a single county or metropolitan area
[8]. Since virtually all patients diagnosed with endocarditis are
hospitalized, we analyzed a nationally representative sample of US
hospital discharges between 1998 and 2009 to document the
further evolution of this disease in the 21
st century.
Methods
Ethics Statement
Because the study involved only secondary analysis of data
available in the public domain, it was exempt from ethics review.
We analyzed the Agency for Healthcare Research and Quality’s
Nationwide Inpatient Sample (NIS) for 1998–2009 which provides
hospital discharge data for about 8 million inpatient stays annually
from a 20% sample of non-federal acute care hospitals [9] (http://
www.hcup-us.ahrq.gov/nisoverview.jsp). The NIS provides
weights to allow extrapolation to all US hospitalizations. Prior to
2009, the NIS included up to 15 diagnosis codes and 15 procedure
codes from each patient’s hospital discharge abstract, using the
International Classification of Diseases, 9
th Revision, Clinical
Modification (ICD-9-CM). The 2009 NIS includes ten additional
diagnoses for a total of 25.
The NIS also provides data on age, sex, race, expected source of
payment, the income quartile of patients’ zip code of residence,
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facility), hospital charges and hospital characteristics.
We considered a patient to have infective endocarditis (IE) if
their record included any of the following diagnostic codes: 4210
(acute and subacute bacterial endocarditis), 4211 (acute and
subacute infective endocarditis in diseases classified elsewhere –
e.g. Q fever), 4219 (acute endocarditis, unspecified), 03642
(meningococcal endocarditis), 09884 (gonococcal endocarditis),
11281(candidal endocarditis) or 1154 (histoplasmosis endocarditis).
We excluded endocarditis due to syphilis, rheumatic heart disease
(without infection), lupus or other non-infectious causes.
The Appendix lists the ICD-9-CM codes we used to identify
causative organisms, comorbidities, predisposing factors, proce-
dures during hospitalization, and complications.
The ICD-9-CM does not include a specific code identifying
culture-negative endocarditis. Hence, the lack of a bacteriologic
diagnosis may sometimes indicate failure to code a known
causative organism. To explore the characteristics of patients
lacking a specific bacteriologic diagnosis we compared the
characteristics of this group to patients for whom a causative
organism was coded.
Data Analysis
We first calculated the number of hospital stays for which a
diagnosis of endocarditis was coded. Because about 9.9% of
endocarditis hospitalizations ended with a transfer to another
acute care hospital, we estimated the number of unique
endocarditis cases by assuming that all transferred patients were
coded as ‘‘endocarditis’’ at the receiving hospital, and subtracting
them from our estimates. Such transferred patients were also
excluded from calculation of death rates. (We could not identify
other patients who might be duplicates in our data, i.e. those who
were discharged and subsequently readmitted during a single
episode of IE. Hence, our estimation of the number of IE cases
may be slightly high). Additionally, we excluded the 0.2% of 2009
records in which endocarditis was coded but not among the first
15 diagnoses. We compared changes in endocarditis hospitaliza-
tion rates between 1998 and 2009 using Census Bureau figures
and the direct method to adjust for population growth and aging
[10,11].
We calculated the proportion of IE hospitalizations due to each
organism in two ways: first, as a proportion of all IE hospitaliza-
tions and then as a proportion of these with at least one organism
coded. We analyzed IE hospitalizations by gender, race and age
group, as well as by hospital characteristics, length of stay (LOS),
expected source of payment, hospital charges, and disposition. In
addition, we examined pre-disposing factors, co-morbidities (see
Appendix), and complications including valve replacement, death,
myocardial infarction (MI), neurological complications or acute
renal failure (ARF).
Statistical Analysis and Considerations
We performed chi square tests to evaluate differences in
proportions, and Cochran-Armitage tests to evaluate time trends.
For continuous variables we used t tests to evaluate differences,
and linear regression to evaluate time trends. Because the NIS
sample size is large, most observed differences (and all of those we
cite) are statistically significant (p,.0001) unless otherwise noted.
Results
Hospital stays for IE rose from 28,195 in 1998 to 43,419 in 2009
(Table 1); this 54.0% increase exceeded the 13.1% growth in total
hospital admissions (p,.0001). After adjustment for the 9.9% of IE
hospital stays that ended in a transfer to another hospital within
the NIS sampling frame, the number of unique endocarditis
hospitalizations was 25,511 in 1998 (9.3 per 100,000 population)
rising to 38, 976 in 2009 (12.7 per 100,000 population) (p,.0001).
After adjustment for population aging and growth, endocarditis
hospitalizations increased by 2.4% annually. Hence, the increase
was not simply due to population aging.
Mean LOS was 15.3 days and varied little over the 12 years of
the study (p=.55). Mean hospital charges more than doubled in
real terms from $45,542 ($59,941 in 2009 dollars) to $122,204.
Adjustment for transfers to other acute care hospitals would
increase these figures by about 10%. Both LOS and charges were
about four times higher than the average for all diagnoses, a ratio
that did not change over time.
Hospital charges and LOS varied little by age among adults
aged 18–69, but were lowest for those 70 and older and highest for
children.
Epidemiology
Table 2 displays demographic features of patients hospitalized
with endocarditis. A majority (57.7%) were male. More than a
third (36.4%) were age 70 and above. Most patients resided in zip
codes with below average incomes. Most hospitalizations occurred
in the South, the census region with the largest population.
However, the Northeast had the highest rate per 100,000
population (15.8), 53% higher than in the Midwest (10.3) or West
(10.3); the South had an intermediate rate (12.1). (All-cause
hospitalization rates are similar in all regions except the West,
where rates were about 20% lower). Among endocarditis patients,
substance use and HIV were most common in the Northeast and
least common in the Midwest.
Table 3 displays comorbidities and predisposing factors.
Between 1998 and 2009 the mean age of endocarditis patients
rose from 58.6 to 60.8 years. This shift reflects stable incidence
rates in younger populations, and substantial increases in all age
groups older than 50 (Figure1). Cases with comorbid drug use,
HIV (or both) fell both absolutely, and as a share of all
endocarditis hospitalizations; the proportion with HIV fell from
4.8% to 1.5%, while the share with a diagnosis of drug use
(narcotics, cocaine or amphetamines) fell from 9.7% to 4.7%. The
proportion of patients with a pre-existing cardiac valve replace-
ment, implant or indwelling device rose 42%, from 13.3% in 1998
to 18.9% in 2009. The proportion on chronic dialysis was 4.4%,
peaking in 2006 before declining.
Microbiology
An organism was coded for 62.3% of IE discharges in 1998,
rising to 69.4% in 2009 (Table 4). Because most case series report
rates of culture-negative endocarditis of less than 10%, it seems
likely that about a quarter of endocarditis patients in the NIS had
known microbiology that was not coded in the discharge
summary. Patients with no coded organism were similar to
patients with a bacteriologic diagnosis according to age, race,
predisposing factors and most complications. However, they were
slightly more likely to undergo valve replacement, to live in the
South or in a poor zip code, be hospitalized in a rural hospital, and
be female. Multiple organisms were mentioned in 4.2% of
discharge records, a number that exceeds previous estimates of
polymicrobial endocarditis. Some of these probably represent a
second infection (e.g. pneumonia) during an endocarditis hospi-
talization. The data below (and in Table 4) should be interpreted
with these caveats in mind.
The most common organism was Staphylococcus aureus,
mentioned in 28.7% of discharge summaries (44.2% of summaries
Infective Endocarditis in the U.S.
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one third, from 24.4% in 1998 to 32.0% in 2009. It was
particularly common among patients with substance use, men-
tioned in 46.9% of those cases. Methicillin resistant S. aureus
(MRSA) accounted for 53.3% of S. aureus among endocarditis
discharges in 2009, the only year in which NIS identified
methicillin-resistance. Other staphylococci were mentioned in
6.7% of discharges. Other organisms showed no marked trends.
Streptococci were mentioned in 24.7% of discharge summaries, of
which more than one quarter were labeled Group D (enterococci).
There was no change in the proportion (nor in overall IE
incidence) of cases attributable to non-enterococcal streptococci
(i.e. cases that might be affected by antibiotic prophylaxis)
coincident with the 2007 change in recommendations regarding
prophylaxis (p=.53 for comparison between rate trend for non-
enterococcal streptococci, 1998–2006 vs. 2008–2009).
Gram-negative bacilli were mentioned in 5.6% of endocarditis
patients’ discharge summaries, and Candida species in 1.0%.
Outcomes
Table 5 summarizes endocarditis outcomes; 14.5% of patients
with a diagnosis of IE died in-hospital. Changes in the death rate
over the 12 years of the study were negligible. The rate of valve
replacement during the hospital stay did not change (p=.92),
averaging 9.6% of patients; 4.6% of mitral valves, and 6.1% of
aortic valves were replaced (some patients underwent both
procedures).
Serious neurological complications (stroke or CNS infection),
MI, and the composite endpoint of these plus death, all increased.
The composite endpoint was met by 25.6% of discharged patients
in 2009, up from 20.3% in 1998. MI rates more than doubled
from 3.2% to 6.8%, while serious neurological complications rose
from 9.2% to 13.3%. Overall, a stroke occurred during 9.0% of
endocarditis hospitalizations, CNS infection during 2.1%, convul-
sions during 3.8%, and encephalopathy during 2.2% of the
hospital stays. ARF was diagnosed in 18.0% of patients.
Patients with S. aureus had significantly higher mortality
(17.4%) than those with other (or no) specified causative organisms
(11.3%), and higher rates of CNS infection (3.9% vs. 1.4%) and
ARF (22.7% vs. 16.0%). The difference in stroke rates was small
(9.6% vs. 8.8%, p=.0005).
Other predictors of mortality included: any neurological
complication (23.3%), especially stroke (28.5%); ARF (27.1%);
and MI (31.6%). Patients over 70 had the highest mortality
(16.1%), while those 18–44 had the lowest (4.8%); 8.5% of
children died. Mortality was not notably affected by HIV, pre-
existing valvular abnormalities, or valve replacement during
hospitalization, but was lower among patients with substance use
(8.3%).
Discussion
The incidence of hospitalization for endocarditis in the U.S. is
12.7 per 100,000 annually. Even accounting for the fact that
multiple hospitalizations might occur during a single episode of IE,
the incidence of this illness appears substantially higher than
previously reported [5,8]. The age adjusted 2.4% annual increase
in hospitalizations between 1998 and 2009 is in keeping with
reports of rising rates of sepsis and septicemia during this period
[12]. However, it represents an acceleration of the trend in IE
incidence observed in a review of twelve small population-based
studies in Europe and Olmsted County, Minnesota [8]. That
review found rates (per 100,000) of 1.4–1.8 during the 1970s and
1980s (with one outlier), rising to 2.2–4.9 during the 1990s.
The IE patients we identified resemble those in a 2000–2005
prospective cohort study of 2,781 patients in 25 countries (ICE-
PC) where 25% of all cases (and 38% of US patients) had health
care-associated infections [5,13]. Several epidemiologic features of
our patients – their advanced age, the male predominance, the
prevalence of co-morbid illness and cardiac implants, grafts and
devices, and the dominant role of S. aureus (and, in 2009, MRSA)
– suggest that health care-associated infections were frequent.
Remarkably, co-morbid drug use and HIV, although probably
under-reported, fell between 1998 and 2009. Perhaps harm
reduction programs stressing needle hygiene, and a shift from
intravenous to oral opioid use underlie this decrease [14].
The rising age of endocarditis patients explained few of our
findings. Although death and MI rates were higher among the
elderly, time trends for these outcomes did not vary by age. The
Table 1. Number of Hospital Stays, and Hospitalized Cases with Diagnosed Infective Endocarditis, Mean Length of Stay and
Hospital Charges, 1998–2009.
Year Number of Hospital Stays
Number of Hospitalized Cases,
Adjusted for Transfers
Mean Length of Stay
(Days) Mean Hospital Charges ($s)
1998 28,195 25,511 15.3 $45,542
1999 29,420 26,583 15.5 $50,752
2000 29,868 27,150 15.1 $57,693
2001 31,526 28,506 15.9 $64,445
2002 32,229 29,399 15.2 $69,853
2003 35,190 31,893 15.6 $85,395
2004 36,660 32,959 15.4 $81,759
2005 37,508 33.615 15.6 $86,515
2006 40,573 36,642 15.3 $90,529
2007 38,207 34,028 15.0 $99,559
2008 41,143 36,892 15.5 $114,576
2009 43,419 38,976 15.0 $122,204
12 Year Total 423,938 382,153 15.3
doi:10.1371/journal.pone.0060033.t001
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slightly higher among the non-elderly (in keeping with findings
from the ICE-PC cohort [15]) and rose faster. The rise in
neurologic complications occurred largely among those under 70,
and this group accounted for the entire decline in HIV and
substance use-associated cases.
We found marked geographic variation in IE hospitalization
rates, with higher rates in poorer communities and in the
Northeast. This finding remains unexplained; differences in all-
cause hospitalization rates and mentions of substance use and HIV
were small. The ICE-PC study also documented marked
geographic variation (by continent) in the epidemiology of IE [5].
The geographic variability we observed may, in part, explain
the lower estimates of IE incidence in earlier studies. For instance,
a widely-cited U.S. study assessed IE incidence in Olmstead
County, Minnesota, a region in the Midwest with a relatively low
poverty rate that may not be nationally representative.
Despite changes in recommendations that greatly reduced the
use of antibiotic prophylaxis for dental and other procedures
around 2007 [16,17], we found no coincident inflection in the time
trend of total IE hospitalizations or of the subset caused by non-
enterococcal streptococci. These reassuring findings mirror those
from England and Wales [18].
Endocarditis outcomes didn’t improve during the 12-year
period we studied - perhaps due to the growing predominance
of S. aureus infections. Severe complications increased. At 14.5%,
mortality was lower than the 18% rate in the ICE-PC study, which
oversampled referral hospitals [5]. Our analysis probably under-
counts deaths; LOS was only 15 days, and some patients
undoubtedly died while completing therapy in convalescent
settings. In one study, 12% of IE patients died within one year
and a third by four years after discharge [19].
The rate of valve replacement surgery we observed is far lower
than the 48.2% who underwent surgical therapy in the ICE-PC
cohort, perhaps because a larger proportion of the ICE-PC
patients were cared for in referral centers [5].
Recent studies report similar neurologic complication rates to
those we found [5,20–22]. In our sample, 9% of IE patients
suffered strokes versus 7.8% to 21% in others’ series. We found
low rates of meningitis and brain abscess, only 2.1%; prior studies
reported meningitis in 5% to 16.5% of patients and brain abscess
in 0% to 4% [20,23]. Our finding that CNS infections and stroke
were more common with S. aureus infection confirms prior
findings [20,21,23]. Some [21], but not all [20] previous studies
have, like ours, found an association between neurologic
complications and mortality.
Inflation-adjusted costs of care doubled between 1998 and
2009, rising at the same rate as costs for other diagnoses despite
the absence of important therapeutic innovations for IE. The cost
increase cannot be attributed to IE patients’ increasing age; costs
were lowest for the oldest age group.
Several caveats apply to our analysis. While the NIS data offers
advantages of sample size, wide geographic coverage, the ability to
assess time trends, and lack of referral bias, ascertainment of
diagnoses depends upon both diagnostic and coding rigor. The
discharge summaries from which the NIS data are compiled serve,
in part, as the basis for hospital payment, and are hence subject to
regulation and audit. Hospitals are supposed to code all diagnoses
treated during the stay. Major diagnoses and procedures (e.g.
endocarditis or valve replacement) are unlikely to go uncoded, or
to be affected by changes in coding practices during our study
period. Conversely, regulations proscribe coding for inactive
problems and those not treated during the hospital stay (e.g. a
history of IE); hospitals that billed for IE in the absence of active
infection would be subject to sanctions.
To explore whether over-diagnosis might explain the high
incidence of endocarditis we found, we examined hospitalizations
in which the IE diagnosis was not listed first. In such cases the most
common first diagnoses were conditions closely associated with IE
such as sepsis or ‘‘complication of an implanted device’’.
Similarities in patient demographics, organisms, outcomes and
cost between patients whose IE was coded as a first vs. subsequent
diagnosis suggests that our case ascertainment strategy accurately
reflects physicians’ diagnoses of IE.
However, predisposing factors or complications are probably
under-coded, since clinicians and coders might not consider them
important to patients’ care or to reimbursement. Hence, the NIS
likely under-reports conditions such as intermittent drug use,
anatomically abnormal but functionally adequate heart valves, the
presence of a pacemaker, or the occurrence of a single seizure or
brief bout of ARF.
Table 2. Demographic, Other Patient, and Hospital
Characteristics of Patients Hospitalized with Endocarditis,
1998–2009.
Characteristic Percent
Age
,18 1.9
18–44 20.0
45–59 24.4
60–69 17.4
.69 36.4
Male 57.7
Race/ethnicity*
White 69.4
Black 17.1
Hispanic 8.4
Asian or Pacific Islander 2.0
Native American 0.6
Other 2.6
Insurance**
Private 24.2
Medicare 53.3
Medicaid 13.8
Self-pay/no charge 5.9
Other 2.9
Region
Northeast 24.4
South 36.2
Midwest 19.8
West 19.6
Mean income of zip code of patient’s residence
Poorest quartile 28.3
Second quartile 25.4
Third quartile 23.4
Wealthiest quartile 23.0
*Information on patients’ race was not reported for 21.3% of patents.
**Expected primary payer as indicated by hospital.
doi:10.1371/journal.pone.0060033.t002
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hospitalization. Hence, we cannot ascertain whether a valve
surgery that occurred during an IE hospitalization represented a
cause or a treatment of the infection. However, few cases of early
prosthetic valve IE acquired during surgery would come to light
prior to discharge.
Our hospital-based analysis may underestimate population IE
incidence. Some IE patients may die prior to a hospital admission
or (rarely) be diagnosed and treated without being admitted.
Similarly, we could not identify hospitalized cases whose IE was
never identified and who either died or were cured by treatment
for another condition such as osteomyelitis. Our downward
adjustment to account for transfers to another hospital probably
causes underestimation of the number of unique cases; it assumes
that all cases were coded as having IE at the receiving hospital.
On the other hand, as emphasized above, some patients are
probably double-counted in our analysis because they underwent
more than one hospital admission in the course of a single episode
of IE. We would expect such readmissions to be more frequent at
hospitals which often complete treatment in the outpatient setting.
However, recent IE case series from such institutions indicate that
such readmission are uncommon 23% to 5% of all admitted IE
patients [24,25]. In any event, it seems unlikely that readmissions
of outpatient-treated cases accounts for the sharp upswing in IE
admissions we observed. While we’re unaware of any national data
on trends in the frequency of outpatient IE treatment, the stable
length of IE inpatient stay during the course of our study argues
against a large increase in outpatient therapy.
The major caveat is that, unlike case series that include only
verified and adjudicated diagnoses, we examined clinically
Figure 1. Infective endocarditis hospitalizations: rate per thousand population according to 5 year age groups: 1998 and 2009.
doi:10.1371/journal.pone.0060033.g001
Table 3. Comorbidities and Predisposing Factors Among Cases of Diagnosed Infective Endocarditis, 1998–2009.
Year
Mean Age of
Patients HIV (%) Drug use (%)* Chronic Dialysis (%)
Cardiac Device,
Implant or Graft
(Including valve)(%)
Any Pre-existing Cardiac
Abnormality** (%)
1998 58.7 4.8 9.7 1.8 13.3 23.7
1999 58.8 4.6 9.6 3.0 13.6 22.8
2000 59.8 3.2 7.1 2.6 14.4 23.8
2001 59.6 3.3 8.4 3.1 14.4 24.7
2002 59.4 3.4 8.7 3.6 14.4 24.6
2003 59.2 2.5 8.2 3.9 15.0 25.4
2004 58.9 2.2 9.0 4.7 14.8 24.9
2005 60.0 2.2 8.8 5.8 15.5 25.6
2006 59.5 2.9 8.4 7.5 15.6 26.4
2007 60.6 2.3 7.6 6.6 16.0 27.0
2008 60.9 1.8 5.4 4.0 17.8 26.3
2009 60.8 1.5 4.7 4.6 18.9 27.7
12 Year Total 59.7 2.8 7.8 4.4 15.5 25.4
*Narcotic, amphetamine, or cocaine use
**Includes a coded congenital anomaly, rheumatic and syphilitic heart disease, or the presence of a cardiac device, implant, or graft.
doi:10.1371/journal.pone.0060033.t003
Infective Endocarditis in the U.S.
PLOS ONE | www.plosone.org 5 March 2013 | Volume 8 | Issue 3 | e60033diagnosed IE. Hence, our findings reflect the over-diagnosis (and
perhaps under-diagnosis) of IE in actual clinical practice, where
physicians must sometimes presumptively treat IE despite incon-
clusive blood culture and echocardiographic data. In von Reyn’s
sentinel study [25], the first to apply the now standard [26], strict
definitions of endocarditis, and in the recent prospective ICE-PS
study [5], only 85% of clinically diagnosed cases met strict criteria
for IE. A 15% downward adjustment would reduce our incidence
estimate to 10.8 IE hospitalizations annually per 100,000, a figure
that is still about twice previous U.S. estimates. Unless diagnosis
accuracy is deteriorating, over-diagnosis could not explain the
temporal increase we observed.
IE is much more common than previously believed and
continues to increase due to the increasing incidence among
individuals 50 and older. Rising numbers of cases of IE are due to
S. aureus or associated with cardiac devices and implants, and a
falling number is linked to drug use. These trends point to the
growing importance of patient safety measures to minimize health
care-acquired infection. The marked geographic variation we
observed remains unexplained, suggesting the salience of future
research on Staphylococcal virulence factors as well as environ-
mental and social factors associated with IE.
Appendix
Identifying causative organisms. Although the ICD-9-CM
includes diagnostic codes identifying specific causative organisms
for infectious diseases, only about two-thirds of records carrying a
diagnosis of endocarditis included an indication of a causative
organism. We considered a patient with endocarditis to have a
staphylococcus aureus endocarditis if any of the following
diagnostic codes were included among his/her diagnoses: 03811,
03812, 04111, 04112. Other staphylococci were identified using
the following diagnostic codes: 0381, 03810, 03819, 0411, 04110,
04119. Streptococcal endocarditis was identified by the presence
of diagnostic codes 0380, 0382, 0410, 04100, 04101, 04102,
04103, 04104, 04105, 04109; enterococcal endocarditis by 04104;
gram negative endocarditis by 04185, 0384, 03840, 03841, 03842,
03843, 03844, 03849, 0413, 0414, 0415, 0416, 0417; anaerobic
endocarditis by 0383, 04182, 04183, 04184; other bacterial
endocarditides by 0388, 04189, 04181, 09884, 0830, 0020,
03642; and fungal endocarditis by 1160, 1154, 11281.
Identifying comorbidities, predisposing factors and
complications of endocarditis. We identified comorbidities
and predisposing factors to endocarditis using the following ICD-
9-CM diagnostic codes: For HIV infection: 042, v08, 07953; for
Table 4. Proportion of Cases of Infective Endocarditis Due to Specific Organisms, 1998–2009.
Organism % of All Cases % of Cases With Known Organism
Staphylococcus aureus* 28.7% 44.2%
Other staphylococci 6.7% 10.3%
Streptococci 24.7% 38.0%
Group A 0.7% 1.1%
Group B 1.3% 2.0%
Group C 0.1% 0.2%
Group D (enterococci) 6.4% 9.8%
Group G 0.2% 0.3%
S. pneumoniae 0.4% 0.6%
Gram negative rods 5.6% 8.6%
E. coli 1.7% 2.6%
Pseudomonas 1.2% 1.8%
Proteus 0.2% 0.3%
Serratia 0.1% 0.2%
H. influenza 0.2% 0.3%
Klebsiella 0.6% 0.9%
Meningococci 0.01% 0.02%
Gonococci 0.02% 0.03%
Anaerobes 0.4% 0.6%
Q Fever 0.04% 0.1%
Mycoplasma 0.01% 0.02%
S. typhi ,0.01% ,0.01%
Candida 1.0% 1.5%
Other fungi ,0.01% ,0.01%
Psittacosis ,0.01% ,0.01%
Other bacteria (species unknown or unspecified) 2.2% 3.4%
No microbiology coded 35.1% NA
More than one organism coded** 4.2% 6.5%
*In 2009, 53.3% of staphylococci were coded as ‘‘methicillin resistant’’ (MRSA). MRSA was not specifically coded in prior years.
**Some cases may represent a second, non-endocarditis infection.
doi:10.1371/journal.pone.0060033.t004
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30560, 30570, 30551, 30561, 30571, 30552, 30562, 30572, 3040,
30400, 30401, 30402, 3042, 30420, 30421, 30422, 3044, 30440,
30441, 30442, 3047, 30470, 30471, 30472, 3048, 30480, 30481,
30482, 3049, 30490, 30491, or 30492; and for patient who were
on renal dialysis prior to their endocarditis hospitalization V451
and V4511. We identified pre-existing cardiac abnormalities that
predispose to infective endocarditis using the following diagnostic
codes: for congenital cardiac anomalies: 7464, 7461, 7466, 74600,
74601, 74602, 74609, 7462, 7463, 7464, 7465, 7465, 7467, 7469,
7468, 74681, 74682, 74683, 74684; for chronic rheumatic heart
disease: 3950, 3951, 3952, 3953, 3959, 394, 3940, 3941, 3942,
3949, 396, 3960, 3961, 3962, 3963, 3968, 3969, 397, 3970, 3971,
3979, 398, 3989, 39890, 39891, 3989, 39899; for syphilitic heart
disease: 0932, 09320, 09321, 09322, 09323, 09324; and for the
presence of a cardiac device, implant, or graft: 9960, 99600,
99601, 99602, 99604, 99661, v433, v4501, v450, v4500, v4502.
We used the following procedure codes to identify patients who
underwent cardiac valve replacement during their endocarditis
hospitalization: 3521, 3522, 3523, 3524, 3520, 3525, 3526, 3527.
We classified patients as having a possible complication of
endocarditis using the following diagnostic codes: for acute renal
failure 5845, 5847, 5848, 5849, 5846, 584; for myocardial
infarction 41000, 41001, 41002, 41010, 41011, 41012, 41020,
41021, 41022, 41030, 41031, 41032, 41040, 41041, 41042, 41050,
41051, 41052, 41061, 41062, 41070, 41071, 41072, 41080, 41081,
41082, 41090, 41091, 41092; for stroke 430, 431, 4320, 4329,
43301, 43311, 43321, 43331, 43381, 43391, 43401, 43411, 43491;
for central nervous system abscess or meningitis 320, 3200, 3201,
3203, 32081, 32082, 32089, 3208, 3209, 11283, 1142, 11501,
11511, 11591, 3240, 3241, 3249; for encephalopathy 3483, 34831,
34830, 34839; and for convulsions 7803,78039 (excludes epilepsy).
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